螺旋断层放疗同步整合推量行风险适应性剂量强化术后放疗用于前列腺癌
该回顾性研究分析了2012年4月至2015年4月间接受根治性前列腺切除术后行螺旋断层放疗的连续前列腺癌患者,采用同步整合推量(SIB)对高危区域(T3/R1)加量至70.3 Gy,前列腺床66.6 Gy,共37次。69例患者中急性2级泌尿和胃肠道毒性分别为10.1%和5.8%,晚期2级泌尿毒性2.9%,无晚期2级胃肠道毒性及3级事件,2年生化无进展生存率为91%。
要点
- 风险适应性剂量强化SIB术后放疗急性2级GU毒性10.1%,GI毒性5.8%。
- 晚期2级GU毒性2.9%,无晚期2级GI毒性及3级急性或晚期GU/GI事件。
- 2年生化无进展生存率为91%,患者报告结局与基线无显著差异。
核心结论
- 螺旋断层放疗行风险适应性剂量强化SIB术后放疗可行,急性和晚期GU及GI毒性率良好,IPSS、ICIQ评分及患者报告生活质量无显著变化,bPFS率有前景。
研究设计与样本
- 放疗采用同步整合推量技术,高危区域(T3/R1)总剂量70.3 Gy(37次×1.9 Gy),前列腺床总剂量66.6 Gy(37次×1.8 Gy)。
- 主要终点为急性和晚期泌尿生殖道(GU)及胃肠道(GI)毒性,次要终点包括IPSS、ICIQ、QLQ-PR25评分及生化失败率。
- 中位随访20个月(范围8-41个月)。
主要发现
- 7例(10.1%)发生急性2级GU毒性,4例(5.8%)发生急性2级GI毒性。
- 2例(2.9%)发生晚期2级GU毒性,无晚期2级GI毒性,无任何3级急性或晚期GU或GI事件。
- 随访结束时IPSS评分(p=1.0)和ICIQ评分(p=0.87)与基线无显著差异,患者报告生活质量也无显著差异。
- 7例(10.1%)出现生化复发,2年生化无进展生存率(bPFS)为91%。
关键数值与推荐
- 高危区域(T3/R1)SIB剂量:37次×1.9 Gy,总剂量70.3 Gy。
- 前列腺床剂量:37次×1.8 Gy,总剂量66.6 Gy。
- 急性2级GU毒性发生率10.1%,急性2级GI毒性发生率5.8%。
- 晚期2级GU毒性发生率2.9%,无晚期2级GI毒性及3级事件。
- 2年bPFS为91%,生化复发率10.1%。
临床怎么用
- 对于根治性前列腺切除术后有高危因素(T3/R1)或生化失败的患者,可考虑采用螺旋断层放疗行风险适应性剂量强化SIB术后放疗。
- 该方案急性和晚期GU及GI毒性率较低,患者报告泌尿功能和生活质量无显著恶化,可作为临床决策参考。
局限性
- 回顾性研究,样本量69例,中位随访仅20个月,随访时间较短。
- 单中心连续病例分析,缺乏对照组,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative adjuvant radiation therapy (ART) in T3 and R1 prostate cancer as well as salvage radiation therapy (SRT) in case of postoperative biochemical failure (BF) are established treatments. Dose-intensified postoperative radiation therapy (RT) schemes have shown superior biochemical control accompanied by increased toxicity rates. In our study we evaluate a novel risk adapted dose-intensified postoperative RT scheme. METHODS: A consecutive series of prostate cancer patients receiving postoperative RT after radical prostatectomy using helical Tomotherapy between 04/2012 and 04/2015 was analyzed retrospectively. RT was administered using a simultaneous integrated boost (SIB) to the area at risk (37 fractions of 1.9 Gy, total dose: 70.3 Gy) being defined based on histopathological findings (T3/R1 region) and in few cases according to additional diagnostic imaging. The whole prostate bed was treated with a dose of 66.6 Gy (37 fractions of 1.8 Gy). Primary endpoints were acute and late genitourinary (GU) and gastrointestinal (GI) toxicities. Secondary endpoints included patient reported outcome as assessed by the International Prostate Symptom Score (IPSS), the International Consultation on Incontinence questionnaire (ICIQ) and prostate cancer specific Quality of Life questionnaire QLQ-PR25, as well as rates of BF. RESULTS: A total of 69 patients were analyzed. Sixteen patients underwent ART and 53 patients SRT, respectively. The median follow-up was 20 months (range, 8-41 months). Seven (10.1%) and four (5.8%) patients experienced acute grade 2 GU and GI toxicity. Two patients (2.9%) had late grade 2 GU toxicity, whereas no late grade 2 GI nor any grade 3 acute or late GU or GI events were observed. When compared to the baseline IPSS scores (p = 1.0) and ICIQ scores (p = 0.87) were not significantly different at the end of follow-up. Patient reported Quality of life (QoL) showed also no significant difference. A total of seven patients (10.1%) experienced a biochemical recurrence with the 2-year biochemical progression-free survival (bPFS) being 91%. CONCLUSIONS: Postoperative RT for prostate cancer patients with a risk adapted dose-intensified SIB using helical tomotherapy is feasible and associated with favorable acute and late GU and GI toxicity rates, no significant change of IPSS-, ICIQ scores and patient reported QoL and results in promising bPFS rates.
引用
- Beck M, Wust P, Barelkowski T, et al. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy. Radiat Oncol. 2017. PMID: 28793907. doi:10.1186/s13014-017-0862-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。